In a patient with psoriasis and psoriatic arthritis on methotrexate who had a pulmonary embolism, should the PE be considered provoked and is indefinite anticoagulation indicated?

Should This PE Be Considered Provoked? No—Treat as Unprovoked

In a patient with psoriasis and psoriatic arthritis on methotrexate who develops a pulmonary embolism, the PE should be considered unprovoked, and indefinite anticoagulation is indicated if bleeding risk is low to moderate.

Key Reasoning

The critical question is whether methotrexate therapy for psoriatic arthritis constitutes a "transient/reversible risk factor" that would make this PE "provoked." It does not. Here's why:

Methotrexate Is Not a Recognized Provoking Factor

Guidelines define provoked PE as occurring in the presence of temporary or reversible risk factors such as surgery, trauma, immobilization, pregnancy, or oral contraceptive use 1, 2. Methotrexate therapy for chronic inflammatory disease does not appear in any guideline's list of provoking factors.

The Underlying Disease May Increase VTE Risk

Research demonstrates that patients with psoriatic arthritis have an elevated risk of VTE compared to the general population 3, 4. In one UK cohort study, PsA patients prescribed DMARDs (including methotrexate) showed elevated but not statistically significant VTE risk 3. A Canadian cohort found independent predictors for VTE in PsA patients included older age, diabetes, and corticosteroid use—but the baseline VTE incidence was 12 events per 10,000 patient-years 4. This suggests the inflammatory disease itself, not the treatment, contributes to thrombotic risk.

Chronic vs. Transient Risk Factors

The 2012 ACCP guidelines distinguish between PE provoked by surgery (lowest recurrence risk), nonsurgical transient risk factors (intermediate risk), and unprovoked PE (highest recurrence risk, >5% annually) 5. Chronic inflammatory disease requiring ongoing immunosuppression does not fit the "transient" category—the patient will likely continue methotrexate indefinitely for disease control.

Treatment Recommendation

Initial Anticoagulation: 3-6 Months

All guidelines agree on at least 3 months of therapeutic anticoagulation for any PE 5, 1, 2, 6, 7. The 2012 ACCP guidelines recommend 3-6 months for unprovoked PE before reassessing 5.

Extended (Indefinite) Anticoagulation

After completing 3-6 months of initial therapy, this patient should receive indefinite anticoagulation based on:

• 2012 ACCP Guidelines: For first unprovoked PE with low or moderate bleeding risk, suggest extended anticoagulant therapy over stopping at 3 months (Grade 2B) 5
• 2020 ESC Guidelines: Continue oral anticoagulant treatment indefinitely in patients presenting with recurrent VTE or consider for first unprovoked PE 2
• 2020 ASH Guidelines: After completion of primary treatment for unprovoked PE, suggest indefinite antithrombotic therapy over stopping (conditional recommendation, moderate certainty) 6

Bleeding Risk Assessment Is Critical

The recommendation for indefinite anticoagulation assumes low to moderate bleeding risk. If this patient has high bleeding risk, guidelines recommend stopping after 3 months 5. Methotrexate itself can cause hematologic toxicity including pancytopenia 8, 9, which could increase bleeding risk—monitor CBC regularly.

Choice of Anticoagulant

Prefer a direct oral anticoagulant (DOAC) over warfarin 2, 6. Options include:

• Apixaban, rivaroxaban, edoxaban, or dabigatran
• For extended therapy, reduced-dose regimens may be considered: rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily 6, 7
• If using warfarin, target INR 2.5 (range 2.0-3.0) 5, 6

Important caveat: DOACs are contraindicated in severe renal impairment 2. Given methotrexate's renal excretion and potential nephrotoxicity 8, monitor renal function closely.

Common Pitfalls to Avoid

1. Don't assume chronic medication = provoked PE: Only transient/reversible risk factors qualify
2. Don't stop at 3 months without reassessment: The default for unprovoked PE is indefinite therapy unless bleeding risk is high
3. Don't ignore the inflammatory disease: PsA itself may contribute to VTE risk independent of treatment 3, 4
4. Don't forget drug interactions: Methotrexate is renally cleared; ensure DOAC dosing accounts for renal function 8
5. Reassess periodically: Even with indefinite therapy, guidelines recommend annual reassessment of bleeding risk, drug tolerance, and patient preference 2, 6, 7

Monitoring During Extended Anticoagulation

• Reassess bleeding risk, hepatic and renal function at regular intervals 2
• Monitor for methotrexate toxicity (CBC, liver function tests) as this could increase bleeding risk 8
• Annual shared decision-making discussions about continuing anticoagulation 7